vs
DYNAVAX TECHNOLOGIES CORP（DVAX）与READING INTERNATIONAL INC（RDI）财务数据对比。点击上方公司名可切换其他公司
DYNAVAX TECHNOLOGIES CORP的季度营收约是READING INTERNATIONAL INC的1.9倍（$94.9M vs $50.3M），DYNAVAX TECHNOLOGIES CORP净利率更高（28.4% vs -5.1%，领先33.5%），DYNAVAX TECHNOLOGIES CORP同比增速更快（17.7% vs -14.2%），DYNAVAX TECHNOLOGIES CORP自由现金流更多（$32.6M vs $4.1M），过去两年DYNAVAX TECHNOLOGIES CORP的营收复合增速更高（30.6% vs 5.6%）
Dynavax Technologies Corp是一家处于商业化阶段的生物制药企业，专注于研发和生产针对传染病的创新疫苗及免疫疗法，核心上市产品为成人乙肝疫苗Heplisav-B，主要市场覆盖北美与欧洲，同时拥有多款针对未满足公共卫生需求的在研产品。
雷丁公司是总部位于美国费城的铁路企业，1924年起在宾夕法尼亚州东部及周边各州提供客运与货运运输服务，直至1976年被联合铁路公司收购。
DVAX vs RDI — 直观对比
营收规模更大
DVAX
是对方的1.9倍
$50.3M
营收增速更快
DVAX
高出31.8%
-14.2%
净利率更高
DVAX
高出33.5%
-5.1%
自由现金流更多
DVAX
多$28.5M
$4.1M
两年增速更快
DVAX
近两年复合增速
5.6%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $94.9M | $50.3M |
| 净利润 | $26.9M | $-2.6M |
| 毛利率 | — | — |
| 营业利润率 | 22.4% | -1.9% |
| 净利率 | 28.4% | -5.1% |
| 营收同比 | 17.7% | -14.2% |
| 净利润同比 | 53.0% | -14.5% |
| 每股收益（稀释后） | $0.21 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DVAXRDI
| Q4 25 | — | $50.3M | ||
| Q3 25 | $94.9M | $52.2M | ||
| Q2 25 | $95.4M | $60.4M | ||
| Q1 25 | $68.2M | $40.2M | ||
| Q4 24 | $72.0M | $58.6M | ||
| Q3 24 | $80.6M | $60.1M | ||
| Q2 24 | $73.8M | $46.8M | ||
| Q1 24 | $50.8M | $45.1M |
净利润DVAXRDI
| Q4 25 | — | $-2.6M | ||
| Q3 25 | $26.9M | $-4.2M | ||
| Q2 25 | $18.7M | $-2.7M | ||
| Q1 25 | $-96.1M | $-4.8M | ||
| Q4 24 | $7.0M | $-2.2M | ||
| Q3 24 | $17.6M | $-7.0M | ||
| Q2 24 | $11.4M | $-12.8M | ||
| Q1 24 | $-8.7M | $-13.2M |
营业利润率DVAXRDI
| Q4 25 | — | -1.9% | ||
| Q3 25 | 22.4% | -0.6% | ||
| Q2 25 | 15.1% | 4.8% | ||
| Q1 25 | -34.7% | -17.2% | ||
| Q4 24 | -2.3% | 2.6% | ||
| Q3 24 | 12.5% | -0.6% | ||
| Q2 24 | 7.0% | -16.4% | ||
| Q1 24 | -35.0% | -16.7% |
净利率DVAXRDI
| Q4 25 | — | -5.1% | ||
| Q3 25 | 28.4% | -8.0% | ||
| Q2 25 | 19.6% | -4.4% | ||
| Q1 25 | -141.0% | -11.8% | ||
| Q4 24 | 9.8% | -3.8% | ||
| Q3 24 | 21.8% | -11.7% | ||
| Q2 24 | 15.4% | -27.4% | ||
| Q1 24 | -17.2% | -29.4% |
每股收益（稀释后）DVAXRDI
| Q4 25 | — | $-0.11 | ||
| Q3 25 | $0.21 | $-0.18 | ||
| Q2 25 | $0.14 | $-0.12 | ||
| Q1 25 | $-0.77 | $-0.21 | ||
| Q4 24 | $0.07 | $-0.11 | ||
| Q3 24 | $0.12 | $-0.31 | ||
| Q2 24 | $0.08 | $-0.57 | ||
| Q1 24 | $-0.07 | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $160.2M | $10.5M |
| 总债务越低越好 | — | $185.1M |
| 股东权益账面价值 | $534.1M | $-18.2M |
| 总资产 | $946.5M | $434.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DVAXRDI
| Q4 25 | — | $10.5M | ||
| Q3 25 | $160.2M | $8.1M | ||
| Q2 25 | $99.1M | $9.1M | ||
| Q1 25 | $51.7M | $5.9M | ||
| Q4 24 | $95.9M | $12.4M | ||
| Q3 24 | $119.3M | $10.1M | ||
| Q2 24 | $112.5M | $9.3M | ||
| Q1 24 | $132.0M | $7.5M |
总债务DVAXRDI
| Q4 25 | — | $185.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $202.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益DVAXRDI
| Q4 25 | — | $-18.2M | ||
| Q3 25 | $534.1M | $-12.1M | ||
| Q2 25 | $494.2M | $-7.7M | ||
| Q1 25 | $530.9M | $-8.1M | ||
| Q4 24 | $596.8M | $-4.4M | ||
| Q3 24 | $681.4M | $1.6M | ||
| Q2 24 | $642.8M | $6.5M | ||
| Q1 24 | $618.5M | $18.0M |
总资产DVAXRDI
| Q4 25 | — | $434.9M | ||
| Q3 25 | $946.5M | $435.2M | ||
| Q2 25 | $918.4M | $438.1M | ||
| Q1 25 | $945.9M | $441.0M | ||
| Q4 24 | $986.3M | $471.0M | ||
| Q3 24 | $1.1B | $495.7M | ||
| Q2 24 | $1.0B | $494.9M | ||
| Q1 24 | $986.6M | $494.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $33.8M | $4.3M |
| 自由现金流经营现金流 - 资本支出 | $32.6M | $4.1M |
| 自由现金流率自由现金流/营收 | 34.4% | 8.2% |
| 资本支出强度资本支出/营收 | 1.3% | 0.3% |
| 现金转化率经营现金流/净利润 | 1.26× | — |
| 过去12个月自由现金流最近4个季度 | $80.5M | $-2.9M |
8季度趋势，按日历期对齐
经营现金流DVAXRDI
| Q4 25 | — | $4.3M | ||
| Q3 25 | $33.8M | $295.0K | ||
| Q2 25 | $23.4M | $1.6M | ||
| Q1 25 | $-19.6M | $-7.7M | ||
| Q4 24 | $53.0M | $8.0M | ||
| Q3 24 | $19.5M | $1.3M | ||
| Q2 24 | $10.7M | $-10.4M | ||
| Q1 24 | $-16.7M | $-2.8M |
自由现金流DVAXRDI
| Q4 25 | — | $4.1M | ||
| Q3 25 | $32.6M | $-246.0K | ||
| Q2 25 | $22.0M | $1.2M | ||
| Q1 25 | $-23.6M | $-8.0M | ||
| Q4 24 | $49.5M | $7.0M | ||
| Q3 24 | $18.1M | $-1.1M | ||
| Q2 24 | $9.9M | $-10.6M | ||
| Q1 24 | $-17.4M | $-4.7M |
自由现金流率DVAXRDI
| Q4 25 | — | 8.2% | ||
| Q3 25 | 34.4% | -0.5% | ||
| Q2 25 | 23.0% | 1.9% | ||
| Q1 25 | -34.6% | -19.8% | ||
| Q4 24 | 68.8% | 12.0% | ||
| Q3 24 | 22.5% | -1.8% | ||
| Q2 24 | 13.5% | -22.7% | ||
| Q1 24 | -34.3% | -10.4% |
资本支出强度DVAXRDI
| Q4 25 | — | 0.3% | ||
| Q3 25 | 1.3% | 1.0% | ||
| Q2 25 | 1.5% | 0.6% | ||
| Q1 25 | 5.8% | 0.6% | ||
| Q4 24 | 4.8% | 1.7% | ||
| Q3 24 | 1.7% | 4.0% | ||
| Q2 24 | 1.1% | 0.5% | ||
| Q1 24 | 1.5% | 4.3% |
现金转化率DVAXRDI
| Q4 25 | — | — | ||
| Q3 25 | 1.26× | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 7.52× | — | ||
| Q3 24 | 1.11× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
